|
|
 |
|
Viewing report
|
|
|
|
R&D Trends: Hepatitis C
Datamonitor, March 2011, Pages: 46
Introduction
Pegylated interferon in combination with ribavirin is the current standard of care for hepatitis C. While effective in patients infected with genotypes 2 and 3, this regimen has limited efficacy against genotype 1. In light of this, companies are focusing developmental efforts on patients infected with genotype 1 and those that have failed a prior course of pegylated interferon/ribavirin therapy.
Features and benefits
- Overview of the clinical pipeline for hepatitis C along with an assessment of the key R&D trends.
- Analysis of current clinical trial design and various strategies pursued for hepatitis C drug development
- Discussion of the future of clinical trial design and how it will evolve once new products and classes reach the market.
- Review of feedback from key opinion leaders on the future of hepatitis C therapy
Highlights
- The approval of Vertex’s and Tibotec/Johnson & Johnson’s telaprevir and Merck and Co.’s boceprevir will have a significant impact on the current treatment paradigm. Should both drugs successfully reach the market in 2011, triple combination therapy is set to become the new standard of care for patients infected with hepatitis C genotype 1.
- Add-on therapy to current standard of care, interferon-sparing regimens using combinations of small molecule antivirals alone, and interferon-replacement using newer interferon products are the main strategies being investigated for hepatitis C treatment.
- While several companies are pursuing the development of interferon sparing regimens, trial data to date indicates that interferon helps maintain viral suppression and slows down resistance development. Datamonitor believes that interferon-sparing regimens will not be widely adopted in the short- to mid-term future, at least.
Your key questions answered
- Gain an insight into key trends in the hepatitis C pipeline and drugs currently in development.
- Assess the changes in clinical trial design as products advance in clinical development.
- Understand the impact of new product approvals on current treatment algorithms.
|
|
|
|
